Monday, September 25, 2023
Chime Biologics and Panolos Bioscience have entered into global strategic collaboration agreement for the development of an innovative multi-specific protein drug.
The collaboration aims to advance the development of PB203, an innovative multi-specific protein drug with a specific focus on combatting solid tumours, notably pancreatic ductal adenocarcinoma (PDAC) and intrahepatic cholangiocarcinoma (ICC). PB203 is currently in the preclinical phase, and there are imminent plans to progress to Phase I clinical trials in the United States.
The key aspect of this collaboration is Chime's utilisation of its proprietary CHOrus platform, renowned for its exceptional productivity, rapidity, and stability in cell line development. The CHOrus platform will facilitate the selection of the most optimal and stable expression clones based on factors such as expression titre and quality.
This collaboration with Chime Biologics, a globally renowned Contract Development and Manufacturing Organisation (CDMO), holds the promise of bringing renewed hope and transformative treatments to patients worldwide.
This collaboration with Panolos Bioscience aim to advance project in Wuhan, China, taking advantage of Chime's CHOrus cell line development platform. This platform not only facilitates the progression of clinical trials in the United States but also opens the door to global sampling.
